QQQ   439.43 (+0.96%)
AAPL   180.77 (-0.36%)
MSFT   411.42 (+0.91%)
META   489.74 (+1.18%)
GOOGL   137.92 (+1.13%)
AMZN   175.71 (+1.47%)
TSLA   202.17 (+0.06%)
NVDA   799.33 (+2.92%)
NIO   5.71 (+5.16%)
AMD   192.15 (+8.84%)
BABA   74.00 (-0.79%)
T   16.95 (-0.06%)
F   12.44 (+1.14%)
MU   90.28 (+0.64%)
CGC   3.30 (-1.79%)
GE   157.04 (+0.92%)
DIS   111.83 (+0.93%)
AMC   4.33 (-13.23%)
PFE   26.63 (-1.52%)
PYPL   60.20 (-0.08%)
XOM   104.76 (+0.42%)
QQQ   439.43 (+0.96%)
AAPL   180.77 (-0.36%)
MSFT   411.42 (+0.91%)
META   489.74 (+1.18%)
GOOGL   137.92 (+1.13%)
AMZN   175.71 (+1.47%)
TSLA   202.17 (+0.06%)
NVDA   799.33 (+2.92%)
NIO   5.71 (+5.16%)
AMD   192.15 (+8.84%)
BABA   74.00 (-0.79%)
T   16.95 (-0.06%)
F   12.44 (+1.14%)
MU   90.28 (+0.64%)
CGC   3.30 (-1.79%)
GE   157.04 (+0.92%)
DIS   111.83 (+0.93%)
AMC   4.33 (-13.23%)
PFE   26.63 (-1.52%)
PYPL   60.20 (-0.08%)
XOM   104.76 (+0.42%)
QQQ   439.43 (+0.96%)
AAPL   180.77 (-0.36%)
MSFT   411.42 (+0.91%)
META   489.74 (+1.18%)
GOOGL   137.92 (+1.13%)
AMZN   175.71 (+1.47%)
TSLA   202.17 (+0.06%)
NVDA   799.33 (+2.92%)
NIO   5.71 (+5.16%)
AMD   192.15 (+8.84%)
BABA   74.00 (-0.79%)
T   16.95 (-0.06%)
F   12.44 (+1.14%)
MU   90.28 (+0.64%)
CGC   3.30 (-1.79%)
GE   157.04 (+0.92%)
DIS   111.83 (+0.93%)
AMC   4.33 (-13.23%)
PFE   26.63 (-1.52%)
PYPL   60.20 (-0.08%)
XOM   104.76 (+0.42%)
QQQ   439.43 (+0.96%)
AAPL   180.77 (-0.36%)
MSFT   411.42 (+0.91%)
META   489.74 (+1.18%)
GOOGL   137.92 (+1.13%)
AMZN   175.71 (+1.47%)
TSLA   202.17 (+0.06%)
NVDA   799.33 (+2.92%)
NIO   5.71 (+5.16%)
AMD   192.15 (+8.84%)
BABA   74.00 (-0.79%)
T   16.95 (-0.06%)
F   12.44 (+1.14%)
MU   90.28 (+0.64%)
CGC   3.30 (-1.79%)
GE   157.04 (+0.92%)
DIS   111.83 (+0.93%)
AMC   4.33 (-13.23%)
PFE   26.63 (-1.52%)
PYPL   60.20 (-0.08%)
XOM   104.76 (+0.42%)

Should Investors Buy or Sell the Vaccinex Patent News?

Should Investors Buy or Sell the Vaccinex Patent News?

Key Points

  • Vaccinex stock shot up over 20% in pre-market trading on news that the biotech company had secured a patent.  
  • The patent will give the company’s lead candidate, pepinemab, some time to be in market without generic competition, should it get approved. 
  • Approval is still over a year away, and there isn’t much to move the stock price other than advancement through clinical trials.  
  • Penny stocks are always volatile and investors should be concerned about some investors taking profits or cutting losses on such a strong move.  
  • 5 stocks we like better than Vaccinex

Shares of Vaccinex, Inc. NASDAQ: VCNX are charging higher on February 7 on news that the clinical-stage biotechnology company secured a patent. VCNX stock increased by more than 20% in pre-market trading on the news. The stock has dropped about 10% since the market opened but is still holding to a gain of about 10%. 

The patent (U.S. Patent #11572408) is for treating cancer with a Semaphorin-4D antibody in combination with an epigenetic modulating agent. Vaccinex is a company at the forefront of developing Semaphorin-4D (SEMA4D) antibody treatments to treat cancer and neurologic diseases like Huntington’s.  

Securing a patent is a key step for clinical-stage companies because it ensures that if they get a drug to market, it will have the field to itself for some time. However, it will likely be at least late 2024 or early 2025 before Vaccinex has an FDA-approved treatment. Investors will have to wait for news like this to generate enthusiasm for VCNX stock.  

What Does Vaccinex Do? 

According to Vaccinex, “SEMA4D is a potent biological effector believed to prevent immune infiltration and induce myeloid suppressor cells in tumors and also triggers neuroinflammation through reactive gliosis in the brain.” The company’s lead drug candidate, pepinemab, is designed to block SEMA4D and potentially increase immune activity against tumors. Pepinemab may also help reprogram immune mechanisms damaged in neurological disorders like Alzheimer’s Disease and Huntington’s Disease. 

Immunotherapy is a branch of gene editing that is becoming increasingly important in understanding how to treat many chronic conditions, including cancer treatment potentially. Vaccinex has several clinical trials at various stages.  

One of the key benefits of this patent is that it adds further proof for pepinemab’s ability as “a novel mechanism of action that enhances activity but does not enhance the toxicity of existing therapies when used in combination.” For example, in one of its ongoing clinical trials, patients receive “Keytruda plus pepinemab for first-line treatment of recurrent or metastatic head and neck cancer.” Keytruda, developed by Merck & Co., Inc. NYSE: MRK is considered the standard of care for this kind of cancer treatment.  


Is There Excitement About VCNX Stock? 

I might not say excitement, but there is interest. Vaccinex stock has 68% institutional ownership. While the stock isn’t being heavily bought, there has been no institutional selling in the last 12 months. There have also been no insiders selling shares in the last 12 months.  

And whereas many penny stocks are subject to heavy short-selling activity, that’s not the case with Vaccinex. Short selling volume is light; even that number is down over 50% in the last month. 

Still, penny stocks are penny stocks for a reason. And Vaccinex is trading for pennies on the dollar. The share price dropped below $1 in August and has stayed there. Investors looking to take a position should be careful of some investors who may take this pop in the company’s stock as a chance to take profits and/or cut their losses.  

→ This is the #1 Stock to Buy for the AI Tidal Wave (From Chaikin Analytics) (Ad)

Should you invest $1,000 in Vaccinex right now?

Before you consider Vaccinex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaccinex wasn't on the list.

While Vaccinex currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Vaccinex (VCNX)
2.2905 of 5 stars
$8.80+0.5%N/A-0.10N/A
Merck & Co., Inc. (MRK)
4.7095 of 5 stars
$127.53-0.5%2.42%910.93Moderate Buy$130.12
Compare These Stocks  Add These Stocks to My Watchlist 

Chris Markoch

About Chris Markoch

  • CTMarkoch@msn.com

Editor & Contributing Author

Retirement, Individual Investing

Experience

Chris Markoch has been an editor & contributing writer for MarketBeat since 2018.

Areas of Expertise

Value investing, retirement stocks, dividend stocks

Education

Bachelor of Arts, The University of Akron

Past Experience

InvestorPlace


Featured Articles and Offers

Search Headlines: